<DOC>
	<DOCNO>NCT01467323</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial evaluate efficacy safety biphasic insulin aspart 30 subject type 1 type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Safety Biphasic Insulin Aspart 30 Type 1 Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Subjects insulin require type 1 type 2 diabetes least 24 month Current treatment human insulin ( either premix short long/intermediate act insulin ) twice daily treatment regimen preparation and/or selfmix least 12 month Body mass index ( BMI ) equal 35.0 kg/m^2 HbA1c equal 11.0 % Total daily insulin dose least 1.4 IU/kg Treatment oral hypoglycaemic agent within month prior inclusion Recurrent severe hypoglycaemia ( judged investigator ) Active proliferative retinopathy Impaired renal function creatinine least 150 mcmol/l ( 1.7 mg/dl ) History pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>